Introduction {#s1}
============

Prior research has produced well-replicated associations between various health maladies (both psychological and medical) and a range of antisocial behaviors (ASB) ([@B1]--[@B4]). Overtly aggressive forms of behavior in particular are correlated with an array of diseases; chronic and acute, communicable and non-communicable, and including diabetes, hepatitis, asthma, hyperlipidemia, cancer, and various attendant medical complications such as sepsis ([@B2], [@B5]--[@B7]). Children and adolescents with psychiatric diagnoses such as attention deficit/hyperactivity disorder (ADHD)---a key risk factor for crime and ASB---are at an increased risk for adverse health outcomes that can include sleep apnea, diabetes, and obesity ([@B8]--[@B10]).

While the evidence regarding phenotypic correlation seems clear, less apparent is whether some covariance between ASB and health indicators also exists at a genomic level ([@B11]). This becomes possible owing to several reasons, including but not limited to the diffuse heritability of quantitative human traits, as well as arguments made regarding the possibility of "omnigenic" influences in nature ([@B12], [@B13]). The purpose of this brief report, then, is to shed light on possible associations between ASB and a wide swath of relevant health, physiological, and disease traits. The findings to come in this area, regardless of their precise outcome, are important as they will have key implications for research on this topic. To the extent that a genetic correlation exists across traits it both suggests a shared etiology for health and ASB, and also highlights the need to better understand mechanistic pathways from genetic to phenotypic variation ([@B12]). Correlated genetic factors must also be controlled in epidemiological and observational studies seeking to explore causal effects running from ASB to health or vice versa ([@B14], [@B15]). An absence of a genetic correlation is also of interest, as it suggests areas where genetic influences are less pleiotropic, and thus will necessarily shape the search for other trait relevant variants for both sets of outcomes independently. Below, we first examine some of the indirect evidence bearing on the current focus. We then transition to the work being done directly on the genomics of antisocial behavior, and discuss reasons why overlap between ASB and health/wellbeing may exist.

The Correlations Between Health, Disease, and ASB-Relevant Outcomes {#s1_1}
-------------------------------------------------------------------

There may exist some shared genetic variance between ASB and health/physiological maladies, but empirical evidence on this question is largely lacking or absent entirely. To be sure, there is reason to suspect that such an association *might* exist. Both sets of outcomes---ASB and health---are moderately heritable ([@B13]). Given the pleiotropy that exists in the genome, moreover, it seems reasonable to hypothesize that some of the variants associated with health and ASB overlap ([@B12]). Finally, phenotypic correlations often reflect genetic correlations to some extent ([@B11]). This last point is not fundamental to the hypotheses being tested per se, however, does seem broadly relevant when considering possible overlapping genomic architectures between outcomes correlated at a phenotypic level.

To illustrate our point, consider the limited results gleaned from prior genome wide association (GWA) based studies which relate to the current topic. As we mentioned above, certain cognitive traits/psychological disorders (i.e., ADHD) can function to increase the risk of ASB while also presenting concurrently with certain health maladies ([@B16]--[@B18]). Hagenaars and colleagues ([@B16]) provide a general summary regarding genomic correlations between cognitive traits and health \[we direct interested readers specifically to their supplementary tables, and studies such as Brainin et al. ([@B19]) and Kovacic et al. ([@B20])\]. It should be reiterated, though, that the studies referenced are illustrative, yet only indirectly related to our current focus. Most research to date has not examined the genomic architectures of ASB directly, thus cannot directly elucidate the research question of interest here.

Better Characterizing the Genomics of Antisocial Behavior {#s1_2}
---------------------------------------------------------

Indeed, to best address the current question a necessary first step involved examining the genomic architectures of various antisocial behaviors. While well-powered genome wide association studies (GWAS) have become widely available in general, comparatively less effort has been focused on antisocial behavioral phenotypes ([@B15], [@B21]). The result, to date, has meant somewhat limited statistical power when examining antisocial behavioral phenotypes (compared to health/disease outcomes). Nonetheless, work in the area is growing, and to address the power problems (as well as other previous limitations), several consortia were formed combining several datasets in order to increase efficiency of research in this area.

Examples of these far-reaching collaborations studying the genetics of ASB include: ACTION (Aggression in Children: Unraveling gene--environment interplay to inform Treatment and InterventION strategies), the Agressotype consortium, BroadABC (Broad Antisocial Behavior Consortium) and EAGLE (Early Genetics and Lifecourse Epidemiology). Using consortia data, we have previously meta-analyzed GWAS data of the non-overlapping cohorts of the BroadABC and EAGLE groups (combined N = 31,968) ([@B22]). Despite the identification of a few promising genetic loci (such as chr1:rs2764450; chr2: rs11126630; chr11:rs11215217; and chrX: rs41456347) these large collaborative GWA efforts have not yet produced robust and reproducible genetic variants associated with ASB ([@B22]).

Still, these consortia have demonstrated a polygenic contribution of common variants to antisocial behavior and revealed genetic overlap of antisocial behavior with several psychological, psychiatric and addictive outcomes. We demonstrated preliminary evidence of a genetic correlation between reproductively relevant traits and ASB, for instance. In particular, genetic correlation analyses suggested that alleles associated with higher reproductive output were positively correlated with alleles associated with ASB, whereas alleles associated with giving birth later in life were negatively associated ([@B23]). Moreover, in a study using a similar research design we found preliminary support for a genetic correlation of ASB with lifetime cannabis use and cigarettes per day, but not with weekly alcohol consumption or ever smoking ([@B24]).

Methods and Results {#s2}
===================

The current brief report expands on the research just mentioned. To maximize sample size, this study included population-based cohorts with a broad range of antisocial measures, covering both aggressive and non-aggressive domains of antisocial behavior, and with different age groups represented \[age ranges for EAGLE included 3 to 15 years old, and BroadABC included ages ranging between 7 and 56 years old; additional details are provided elsewhere, see Pappa et al. ([@B22]); Tielbeek et al. ([@B25])\]. This brief report represents our first exploration examining the genetic overlap of antisocial behavior, utilizing combined summary data from two consortia \[for more detail, see Pappa et al. ([@B22]), Tielbeek et al. ([@B25])\] with 71 traits derived from the centralized database LD Hub ([@B26]) (see Footnote [^1^](#fn1){ref-type="fn"}).

We should momentarily elaborate on the selection and inclusion of health and physiological measures. As mentioned, there are a host of health, physiological, and disease relevant outcomes correlated across numerous prior studies with ASB (see above). As additional GWA summary statistics have become publicly available (see Footnote 1), we opted to cast a wide net when analyzing the possible shared genomic architectures of ASB and health/disease/physiology (as opposed to numerous papers, each smaller in scope).[^2^](#fn2){ref-type="fn"} While desirable in some respects, this approach also further necessitates the need to guard against the possibility of chance findings. With this point in mind, we uncovered no significant (α \< 0.0007) genetic correlations after a Bonferonni correction was applied to the data ([**Table 1**](#T1){ref-type="table"}).

###### 

Genetic correlations (r~g~) between 71 traits (anthropometric, autoimmune, cancer, glycemic, hematological, hormone, kidney, lipids, metal, neurological, sleeping) and broad antisocial behavior.

  Trait Category   Phenotype                                                       Ethnicity   r~g~     SE      p         SNP h^2^
  ---------------- --------------------------------------------------------------- ----------- -------- ------- --------- ----------
  Anthropometric   Child birth length                                              European    0.069    0.212   0.746     0.175
  Anthropometric   Child birth weight                                              European    -0.490   0.251   0.051     0.125
  Anthropometric   Body mass index                                                 European    0.201    0.127   0.114     0.191
  Anthropometric   Body fat                                                        Mixed       0.291    0.159   0.068     0.109
  Anthropometric   Childhood obesity                                               European    0.252    0.176   0.152     0.400
  Anthropometric   Extreme bmi                                                     European    0.165    0.144   0.252     0.694
  Anthropometric   Extreme height                                                  European    0.062    0.110   0.575     0.123
  Anthropometric   Extreme waist-to-hip ratio                                      European    0.109    0.222   0.623     0.353
  Anthropometric   Height_2010                                                     European    0.047    0.090   0.599     0.285
  Anthropometric   Obesity class 1                                                 European    0.185    0.121   0.127     0.217
  Anthropometric   Obesity class 2                                                 European    0.210    0.131   0.108     0.184
  Anthropometric   Obesity class 3                                                 European    0.216    0.172   0.209     0.122
  Anthropometric   Overweight                                                      European    0.136    0.118   0.250     0.110
  Anthropometric   Hip circumference                                               European    0.022    0.091   0.812     0.129
  Anthropometric   Infant head circumference                                       European    0.125    0.254   0.622     0.228
  Anthropometric   Waist circumference                                             European    0.114    0.095   0.233     0.122
  Anthropometric   Waist-to-hip ratio                                              European    0.303    0.126   0.016\*   0.114
  Anthropometric   Difference in height between adolescence and adulthood age 14   European    -0.069   0.272   0.800     0.474
  Anthropometric   Difference in height between childhood and adulthood age 8      European    -0.120   0.217   0.581     0.320
  Anthropometric   Sitting height ratio                                            European    0.320    0.184   0.082     0.227
  Anthropometric   Height Females at age 10 and males at age 12                    European    -0.026   0.179   0.886     0.431
  Anthropometric   Birth weight                                                    European    -0.136   0.121   0.260     0.098
  Autoimmune       Eczema                                                          Mixed       0.400    0.223   0.072     0.069
  Autoimmune       Crohns disease                                                  European    -0.003   0.141   0.983     0.478
  Autoimmune       Inflammatory Bowel Disease (Euro)                               European    -0.228   0.152   0.133     0.300
  Autoimmune       Ulcerative colitis                                              European    -0.391   0.189   0.038\*   0.224
  Autoimmune       Asthma                                                          European    0.051    0.186   0.784     0.142
  Autoimmune       Rheumatoid Arthritis                                            European    0.223    0.144   0.122     0.157
  Autoimmune       Multiple sclerosis                                              European    0.143    0.279   0.609     0.073
  Autoimmune       Systemic lupus erythematosus                                    European    0.089    0.185   0.629     0.408
  Autoimmune       Primary biliary cirrhosis                                       European    0.132    0.221   0.549     0.365
  Autoimmune       Celiac disease                                                  European    0.033    0.265   0.902     0.308
  Autoimmune       Primary sclerosing cholangitis                                  Mixed       -0.556   0.256   0.030\*   0.399
  Cancer           Lung cancer (all)                                               European    0.088    0.185   0.636     0.130
  Cancer           Lung cancer (squamous cell)                                     European    0.228    0.310   0.463     0.048
  Cancer           Lung adenocarcinoma                                             European    0.124    0.309   0.688     0.025
  Cancer           Squamous cell lung cancer                                       European    0.153    0.263   0.560     0.037
  Cancer           Lung cancer                                                     European    0.061    0.173   0.727     0.323
  Glycemic         Type 2 Diabetes                                                 European    -0.143   0.162   0.378     0.090
  Glycemic         Fasting glucose main effect                                     European    0.052    0.150   0.729     0.104
  Glycemic         Fasting insulin main effect                                     European    0.276    0.217   0.202     0.070
  Glycemic         Fasting proinsulin                                              European    -0.274   0.287   0.340     0.189
  Glycemic         2hr glucose adjusted for BMI                                    European    0.033    0.267   0.901     0.109
  Glycemic         HbA1C                                                           European    0.264    0.257   0.305     0.064
  Glycemic         HOMA-B                                                          European    0.346    0.213   0.104     0.087
  Glycemic         HOMA-IR                                                         European    0.574    0.270   0.034\*   0.068
  Haemotological   Heart rate                                                      Mixed       0.116    0.143   0.416     0.082
  Haemotological   Mean platelet volume                                            European    0.155    0.182   0.396     0.323
  Haemotological   Platelet count                                                  European    -0.130   0.152   0.391     0.132
  Hormone          Leptin_adjBMI                                                   European    -0.101   0.214   0.637     0.094
  Hormone          Leptin_not_adjBMI                                               European    0.054    0.218   0.803     0.098
  Kidney           Urinary albumin-to-creatinine ratio (non-diabetes)              European    -0.191   0.240   0.426     0.055
  Kidney           Chronic Kidney Disease                                          Mixed       -0.152   0.230   0.508     0.020
  Kidney           Serum creatinine (non-diabetes)                                 Mixed       -0.177   0.123   0.150     0.115
  Kidney           Serum creatinine                                                Mixed       -0.144   0.117   0.219     0.108
  Kidney           Serum cystatin c                                                Mixed       -0.207   0.165   0.210     0.170
  Kidney           Urinary albumin-to-creatinine ratio                             European    -0.152   0.222   0.495     0.048
  Lipids           HDL cholesterol                                                 European    0.009    0.121   0.939     0.120
  Lipids           LDL cholesterol                                                 European    0.169    0.130   0.196     0.105
  Lipids           Triglycerides                                                   European    0.129    0.114   0.257     0.174
  Lipids           Total Cholesterol                                               European    0.229    0.127   0.070     0.135
  Metal            Transferrin                                                     European    0.190    0.224   0.396     0.163
  Metal            Ferritin                                                        European    0.173    0.307   0.573     0.094
  Neurological     Alzheimers disease                                              European    0.044    0.211   0.834     0.051
  Neurological     Parkinsons disease                                              European    0.072    0.146   0.622     0.419
  Neurological     Amyotrophic lateral sclerosis                                   European    0.190    0.338   0.575     0.033
  Sleeping         Sleep duration                                                  European    -0.073   0.152   0.630     0.056
  Sleeping         Chronotype                                                      European    0.000    0.119   0.998     0.101
  Sleeping         Insomnia^a^                                                     European    0.425    0.191   0.026\*   0.047
  Sleeping         Insomnia^b^                                                     European    0.300    0.157   0.057     0.133
  Sleeping         Excessive daytime sleepiness                                    European    -0.289   0.174   0.097     0.052

SNP (single nucleotide polymorphism); h^2^: narrow-sense heritability based on all SNPs; r~g~: genetic correlation with ASB. Asterisks (\*) indicate a nominal significant genetic correlation (p\<.05). for a, see ([@B27]); for b, see ([@B28]).

Consideration of findings reaching a level of nominally significant (α \< 0.05) results revealed that---with increasing sample size---anthropometric risk factors such as high waist-to-hip ratio (r~g~ = 0.30, P = 0.016) may correlate with genetic risk of ASB. Moreover, the potential positive genetic overlap of ASB with insomnia (r~g~ = 0.43, P = 0.026) and HOMA-IR (Homeostatic Model Assessment for Insulin Resistance, r~g~ = 0.57, P = 0.034) is noteworthy \[for a related reference, see also Rolling et al. ([@B6])\], as well as the negative genetic correlation with autoimmune diseases ulcerative colitis (r~g~ = −0.39, P = 0.038) and primary sclerosing cholangitis (r~g~ = −0.56, P = 0.030). It is key to emphasize, however, that although we report the above moderate to strong genetic correlations, they may in fact reflect *false positive* findings---as they did *not* survive correction for multiple testing. The large standard errors, it is worth noting, reflect the relatively low GWAS sample size for ASB, rendering these results in need of further replicative efforts with larger sample sizes. Finally, in an effort to be as exhaustive as possible beyond our initial analyses, and by making use of the same LD Hub web interface, we calculated the genetic correlations of ASB with an additional 597 health and physiologically relevant traits of the UK Biobank which also recently became available ([**Supplementary Table S1**](#SM1){ref-type="supplementary-material"}; see also our footnote above concerning the inclusion of these additional traits). Similar to our primary findings, none of these correlations survived correction for multiple testing (α \< 8.4 × 10^−5^).

Discussion {#s3}
==========

What this preliminary exploration suggests is that ASB and various health outcomes share virtually no genomic overlap, beyond what might be considered at this point as "nominally significant." Moreover, these findings further suggest that phenotypic associations between ASB and health/physiological outcomes are perhaps phenotypically causal, or mutually impacted by some third *environmental* variable (i.e., spurious, but owing to environmental variables which might include a range of factors such as socioeconomic status, educational attainment, etc.). Keeping that mind, we have several recommendations for future research endeavors examining the overlap of ASB and health/physiological adversities.

Enlarging and Diversifying Samples {#s3_1}
----------------------------------

With growing sample sizes, future polygenic risk scores (PRS) will improve in their prediction of antisocial behavioral traits on the basis of genetic data. Moreover, future PRS for disease outcomes may still be capable of elucidating the risk of ASB and vice versa \[see Demontis et al. ([@B9])\]. Well-powered PRS, such as for Type 1 Diabetes, have great clinical and research potential and have been found useful for classifying adult incident diabetes type and improving newborn screening ([@B29]). Despite the great potential of PRS and precision medicine, a major limitation is the Eurocentric bias and the lack of diversity in genetic studies. Indeed, the underrepresentation of non-European populations in GWAS is problematic as it limits the generalizability and predictive value of PRS for these populations ([@B30]).

Examining Homogeneous Clusters {#s3_2}
------------------------------

Genetic correlations are computed on the basis of GWA summary statistics of the traits of interest. GWA research designs in psychopathology often employ sum-scores or case-control status summarizing a list of items or symptoms. Items included in these types of composite scores can vary considerably, with some examples including: 'hit others when provoked', 'blamed others' and 'had trouble keeping a job', yet all of them load on the broader construct of antisocial behavior ([@B22]). Prior work on neuroticism, however, suggested that the items included were genetically heterogeneous, and thus argued that future studies should examine the trait from the standpoint of homogeneous clusters of relevant alleles ([@B31]). To that end, future scholars may find the framework of genomic SEM (structural equation modeling) useful in delineating homogenous clusters ([@B32]). Taken together, then, the above recommendations will likely be worthwhile, as it will be important to examine genetic overlap between GWAS summary stats of *subtypes* of ASB (or even on the item level) with disease traits or symptoms in future research.

Exploring Causality {#s3_3}
-------------------

With the help of well-powered GWAS it has become increasingly clear that most genes influence multiple biological pathways and traits---a phenomenon commonly termed pleiotropy ([@B12]). Owing to this issue, it becomes crucial to overcome unmeasured confounding and distinguish between causal and spurious risk factors ([@B33], [@B34]). Despite many epidemiological studies being non-experimental, a research technique called Mendelian randomization (MR)---which is a version of the commonly utilized design known as instrumental variables---can strengthen causal inference by considering genes as the instruments in the design ([@B34]). Stated differently, MR studies operate by making use of genetic variants as proxies for the actual (environmental) risk factor of interest ([@B34]). The number of studies utilizing this approach is expanding rapidly, but as a note of caution (echoed previously in prior work) future MR studies on this topic should carefully assess the plausibility of the underlying assumptions when implementing the technique, and preferably combine various MR methods whenever possible ([@B33]).

Mechanisms and Gene--Environment Interplay {#s3_4}
------------------------------------------

For the traits that might evince *preliminary* evidence of a genetic correlation (if the nominal levels of significance are meaningful), much more work---with more statistical power---is needed to understand the mechanisms of such associations. We hesitate to speculate widely, but one possibility could be that the genetic influences shared across traits operate widely on immune system functioning as well as general functioning in the central nervous system. The downstream effect then would be the emergence of both psychological and physiological conditions at certain points in the life course ([@B16]). Additionally, one cannot discount the relevance of gene--environment interplay in two forms: gene--environment interaction (G × E) and gene--environment correlation (rGE) \[in general, see Leppert et al. ([@B35]); Ruisch et al. ([@B36]); Ruisch et al. ([@B37])\].

Indeed, one can envision scenarios such that the impact of trait relevant genes is calibrated based on exposure to environmental insults, including disease or infectious agents \[i.e., G × E; for indirectly related examples see Ruisch et al. ([@B36]); Ruisch et al. ([@B37])\]. Moreover, traits which vary in part because of genetic variation---in this case ASB---might perhaps operate to increase risk of exposure to infectious agents or more broadly, situations where health outcomes could be compromised ([@B36], [@B37]). Future research on this topic will doubtless benefit from exploring the relevancy of rGEs for the intersection of health and ASB. Finally, we should note that interaction with other alleles at additional loci, too, will likely be important for understanding the complex underpinnings of these phenotypes and why their genomic architectures could potentially overlap. In short, the number of research hypotheses awaiting investigation in this area is long, detailed, and it would seem, quite timely.
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